Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

Dirk L. Kienle; Daniel Dietrich; Karin Ribi; Andreas Wicki; Luca Quagliata; Ralph C. Winterhalder; Dieter Koeberle; Daniel Horber; Sara Bastian; Marc Kueng; Piercarlo Saletti; Daniel Helbling; Daniela Baertschi; Alessandro Lugli; Juerg Bernhard; Christiane Andrieu; Roger von Moos

doi:10.1016/j.jgo.2018.11.011

Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

Dirk L. Kienle
, Daniel Dietrich
, Karin Ribi
, Andreas Wicki
, Luca Quagliata
, Ralph C. Winterhalder
, Dieter Koeberle
, Daniel Horber
, Sara Bastian
, Marc Kueng
, Piercarlo Saletti
, Daniel Helbling
, Daniela Baertschi
, Alessandro Lugli
, Juerg Bernhard
, Christiane Andrieu
, Roger von Moos

Careum Hochschule Gesundheit

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

Originalsprache	Englisch
Seiten (von - bis)	304-310
Fachzeitschrift	Journal of Geriatric Oncology
Jahrgang	10
Ausgabenummer	2
DOIs	https://doi.org/10.1016/j.jgo.2018.11.011
Publikationsstatus	Veröffentlicht - 1 März 2019

UN SDGs

Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung

SDG 3 – Gute Gesundheit und Wohlergehen

Zugriff auf Dokument

10.1016/j.jgo.2018.11.011

https://linkinghub.elsevier.com/retrieve/pii/S1879406818302674

Dieses zitieren

Kienle, D. L., Dietrich, D., Ribi, K., Wicki, A., Quagliata, L., Winterhalder, R. C., Koeberle, D., Horber, D., Bastian, S., Kueng, M., Saletti, P., Helbling, D., Baertschi, D., Lugli, A., Bernhard, J., Andrieu, C., & von Moos, R. (2019). Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. Journal of Geriatric Oncology, 10(2), 304-310. https://doi.org/10.1016/j.jgo.2018.11.011

@article{d75b10ca1ed5492386c2a332f090f988,

title = "Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10",

author = "Kienle, \{Dirk L.\} and Daniel Dietrich and Karin Ribi and Andreas Wicki and Luca Quagliata and Winterhalder, \{Ralph C.\} and Dieter Koeberle and Daniel Horber and Sara Bastian and Marc Kueng and Piercarlo Saletti and Daniel Helbling and Daniela Baertschi and Alessandro Lugli and Juerg Bernhard and Christiane Andrieu and \{von Moos\}, Roger",

year = "2019",

month = mar,

day = "1",

doi = "10.1016/j.jgo.2018.11.011",

language = "English",

volume = "10",

pages = "304--310",

journal = "Journal of Geriatric Oncology",

issn = "1879-4068",

publisher = "Elsevier Ltd.",

number = "2",

}

Kienle, DL, Dietrich, D, Ribi, K, Wicki, A, Quagliata, L, Winterhalder, RC, Koeberle, D, Horber, D, Bastian, S, Kueng, M, Saletti, P, Helbling, D, Baertschi, D, Lugli, A, Bernhard, J, Andrieu, C & von Moos, R 2019, 'Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10', Journal of Geriatric Oncology, Jg. 10, Nr. 2, S. 304-310. https://doi.org/10.1016/j.jgo.2018.11.011

Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. / Kienle, Dirk L.; Dietrich, Daniel; Ribi, Karin et al.
in: Journal of Geriatric Oncology, Jahrgang 10, Nr. 2, 01.03.2019, S. 304-310.

Publikation: Beitrag in Fachzeitschrift › Artikel › Begutachtung

TY - JOUR

T1 - Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10

AU - Kienle, Dirk L.

AU - Dietrich, Daniel

AU - Ribi, Karin

AU - Wicki, Andreas

AU - Quagliata, Luca

AU - Winterhalder, Ralph C.

AU - Koeberle, Dieter

AU - Horber, Daniel

AU - Bastian, Sara

AU - Kueng, Marc

AU - Saletti, Piercarlo

AU - Helbling, Daniel

AU - Baertschi, Daniela

AU - Lugli, Alessandro

AU - Bernhard, Juerg

AU - Andrieu, Christiane

AU - von Moos, Roger

PY - 2019/3/1

Y1 - 2019/3/1

U2 - 10.1016/j.jgo.2018.11.011

DO - 10.1016/j.jgo.2018.11.011

M3 - Article

SN - 1879-4068

VL - 10

SP - 304

EP - 310

JO - Journal of Geriatric Oncology

JF - Journal of Geriatric Oncology

IS - 2

ER -

Kienle DL, Dietrich D, Ribi K, Wicki A, Quagliata L, Winterhalder RC et al. Cetuximab monotherapy and cetuximab plus capecitabine as first-line treatment in older patients with RAS- and BRAF wild-type metastatic colorectal cancer. Results of the multicenter phase II trial SAKK 41/10. Journal of Geriatric Oncology. 2019 März 1;10(2):304-310. doi: 10.1016/j.jgo.2018.11.011